keyword
MENU ▼
Read by QxMD icon Read
search

secondary CNS lymphoma

keyword
https://www.readbyqxmd.com/read/28370436/secondary-cns-involvement-of-alk-negative-anaplastic-large-cell-lymphoma
#1
Ajay Major, Zenggang Pan, Manali Kamdar
No abstract text is available yet for this article.
March 28, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28278731/treatment-of-initial-parenchymal-central-nervous-system-involvement-in-systemic-aggressive-b-cell-lymphoma
#2
Marcel Nijland, Anne Jansen, Jeanette K Doorduijn, Roelien H Enting, Jacoline E C Bromberg, Hanneke C Kluin-Nelemans
Central nervous system (CNS) involvement in systemic B-cell non-Hodgkin lymphoma (B-NHL) at diagnosis (sysCNS) is rare. We investigated the outcome of 21 patients with sysCNS, most commonly diffuse large B-cell lymphoma, treated with high dose methotrexate (HD-MTX) and R-CHOP. The median number of cycles of HD-MTX and R-CHOP was 4 (range 1-8) and 6 (range 0-8), respectively. Consolidative whole brain radiotherapy (WBRT) was given to 33% (7/21) patients. With a median follow-up of 44 months the 3-year progression free survival (PFS) and overall survival (OS) were 45% (95%CI 34-56%) and 49% (95%CI 38-60%), respectively...
February 6, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28237865/the-number-of-extranodal-sites-assessed-by-pet-ct-scan-is-a-powerful-predictor-of-cns-relapse-for-patients-with-diffuse-large-b-cell-lymphoma-an-international-multicenter-study-of-1532-patients-treated-with-chemoimmunotherapy
#3
Tarec Christoffer El-Galaly, Diego Villa, Thomas Yssing Michaelsen, Martin Hutchings, Nabegh George Mikhaeel, Kerry J Savage, Laurie H Sehn, Sally Barrington, Jakob W Hansen, Daniel Smith, Kirsty Rady, Karen J Mylam, Thomas S Larsen, Staffan Holmberg, Maja B Juul, Sabrina Cordua, Michael R Clausen, Kristina B Jensen, Hans E Johnsen, John F Seymour, Joseph M Connors, Peter de Nully Brown, Martin Bøgsted, Chan Y Cheah
PURPOSE: Development of secondary central nervous system involvement (SCNS) in patients with diffuse large B-cell lymphoma is associated with poor outcomes. The CNS International Prognostic Index (CNS-IPI) has been proposed for identifying patients at greatest risk, but the optimal model is unknown. METHODS: We retrospectively analysed patients with diffuse large B-cell lymphoma diagnosed between 2001 and 2013, staged with PET/CT and treated with R-CHOP(-like) regimens...
April 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28178710/diagnosis-and-management-of-leukemic-and-lymphomatous-meningitis
#4
REVIEW
Hemant Murthy, Claudio Anasetti, Ernesto Ayala
BACKGROUND: Leukemic and lymphomatous meningitis is a major presentation of primary or secondary central nervous system (CNS) involvement by aggressive lymphomas or acute leukemia. METHODS: The medical literature and ongoing clinical trials were reviewed on the clinical presentation, diagnosis, prognosis, prevention, and treatment of leukemic and lymphomatous meningitis. RESULTS: Treatment for secondary leukemic and lymphomatous meningitis remains unsatisfactory, and efforts should be made to prevent and treat subclinical disease...
January 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28062425/first-reported-case-of-disseminated-nocardia-kroppenstedtii-sp-nov-infection-presenting-with-brain-abscess-and-endocarditis-in-an-immunocompromised-patient-with-mantle-cell-lymphoma-challenges-in-diagnosis-and-treatment
#5
Aneela Majeed, Hafez Mohammad Ammar Abdullah, Waqas Ullah, Mayar Al Mohajer
A 72-year-old man with a history of blastoid variant stage IV relapsed refractory mantle cell lymphoma presented with new central nervous system (CNS) symptoms. Brain imaging was positive for rim-enhancing lesions along with a mitral valve mass on the echocardiogram. It was a challenge to establish the exact aetiology of these lesions in this patient. He was empirically treated with chemotherapy on the presumption that the brain lesions were secondary to progressive malignancy. However, brain biopsy was negative for malignancy and blood cultures were found positive for Nocardia kroppenstedtii sp nov...
January 6, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/27804873/recent-development-in-the-discovery-of-anaplastic-lymphoma-kinase-alk-inhibitors-for-non-small-cell-lung-cancer
#6
Jingru Liu, Shutao Ma
Non-Small Cell Lung Cancer (NSCLC) is an especially aggressive cancer, the optimal drugs for which are still being developed. The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor superfamily. EML4-ALK fusion gene initially identified in patients with NSCLC in 2007 is defined as a new molecular subset, which is highly sensitive to ALK inhibition. Since the first ALK inhibitor, crizotinib, was approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC patients in 2011, ALK has been identified as a promising target for NSCLC therapy...
October 29, 2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27752821/secondary-central-nervous-system-relapse-in-diffuse-large-b-cell-lymphoma-in-a-resource-limited-country-result-from-the-thailand-nationwide-multi-institutional-registry
#7
MULTICENTER STUDY
Kitsada Wudhikarn, Udomsak Bunworasate, Jakrawadee Julamanee, Arnuparp Lekhakula, Suporn Chuncharunee, Pimjai Niparuck, Supachai Ekwattanakit, Archrob Khuhapinant, Lalita Norasetthada, Weerasak Nawarawong, Nisa Makruasi, Nonglak Kanitsap, Chittima Sirijerachai, Kanchana Chansung, Peerapon Wong, Tontanai Numbenjapon, Kannadit Prayongratana, Tawatchai Suwanban, Somchai Wongkhantee, Pannee Praditsuktavorn, Tanin Intragumtornchai
Secondary central nervous system (CNS) relapse is a serious and fatal complication of diffuse large B cell lymphoma (DLBCL). Data on secondary CNS (SCNS) relapse were mostly obtained from western countries with limited data from developing countries. We analyzed the data of 2034 newly diagnosed DLBCL patients enrolled into the multi-center registry under Thai Lymphoma Study Group from setting. The incidence, September 2006 to December 2013 to represent outcome from a resource limited pattern, management, and outcome of SCNS relapse were described...
January 2017: Annals of Hematology
https://www.readbyqxmd.com/read/27713090/a-comprehensive-assessment-of-toxicities-in-patients-with-central-nervous-system-lymphoma-undergoing-autologous-stem-cell-transplantation-using-thiotepa-busulfan-and-cyclophosphamide-conditioning
#8
Michael Scordo, Valkal Bhatt, Meier Hsu, Antonio M Omuro, Matthew J Matasar, Lisa M DeAngelis, Parastoo B Dahi, Craig H Moskowitz, Sergio A Giralt, Craig S Sauter
High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era. Forty-three adult patients with chemosensitive PCNSL or SCNSL underwent TBC-conditioned ASCT between 2006 and 2015...
January 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27687523/second-malignant-neoplasm-following-childhood-cancer-a-nested-case-control-study-of-a-recent-cohort-1987-2004-from-the-childhood-cancer-registry-of-the-rh%C3%A3-ne-alpes-region-in-france
#9
L Casagranda, M Oriol, F Freycon, D Frappaz, Y Bertrand, C Bergeron, D Plantaz, J L Stephan, C Freycon, F Gomez, C Berger, B Trombert-Paviot
From a population-based cohort of cases of first cancers diagnosed between 1987 and 2004, before the patient's age of 15 years, the authors conducted a nested case-control study, matching 64 patients who experienced a second malignant neoplasm (SMN) with 190 controls. SMNs comprised 10 leukemia or myelodysplastic syndromes, 5 lymphomas induced by Epstein-Barr virus after allograft, and 49 solid tumors, including mainly 25 carcinomas (17 of the thyroid), 9 bone sarcomas, and 7 central nervous system (CNS) tumors...
September 2016: Pediatric Hematology and Oncology
https://www.readbyqxmd.com/read/27681999/uterine-but-not-ovarian-female-reproductive-organ-involvement-at-presentation-by-diffuse-large-b-cell-lymphoma-is-associated-with-poor-outcomes-and-a-high-frequency-of-secondary-cns-involvement
#10
Tarec Christoffer El-Galaly, Chan Y Cheah, Martin Hutchings, Nabegh George Mikhaeel, Kerry J Savage, Laurie H Sehn, Sally Barrington, Jakob W Hansen, Mette Ø Poulsen, Daniel Smith, Kirsty Rady, Karen J Mylam, Thomas S Larsen, Staffan Holmberg, Maja B Juul, Sabrina Cordua, Michael R Clausen, Kristina B Jensen, Martin Bøgsted, Hans E Johnsen, John F Seymour, Joseph M Connors, Peter D N Brown, Diego Villa
Involvement of the internal female reproductive organs by diffuse large B-cell lymphoma (DLBCL) is uncommon, and there are sparse data describing the outcomes of such cases. In total, 678 female patients with DLBCL staged with positron emission tomography/computed tomography and treated with rituximab-containing chemotherapy were identified from databases in Denmark, Great Britain, Australia, and Canada. Overall, 27/678 (4%) had internal reproductive organ involvement: uterus (n = 14), ovaries (n = 10) or both (n = 3)...
September 29, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27677656/how-to-facilitate-early-diagnosis-of-cns-involvement-in-malignant-lymphoma
#11
REVIEW
Agnieszka Korfel, Martha Nowosielski, Javier Pardo-Moreno, Francisco Javier Penalver, Gabriele Buda, Hind Bennani, Myrto Costopoulos, Magali Le Garff-Tavernier, Carole Soussain, Mathias Schmid, Jose Alberto Orfao, Michael Glantz
Making the diagnosis of secondary CNS involvement in lymphoma can be difficult due to unspecific signs and symptoms, limited accessibility of brain/myelon parenchyma and low sensitivity and/or specifity of imaging and cerebrospinal fluid (CSF) examination currently available. Areas covered: MRI of the total neuroaxis followed by CSF cytomorphology and flow cytometry are methods of choice when CNS lymphoma (CNSL) is suspected. To reduce the numerous pitfalls of these examinations several aspects should be considered...
November 2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/27570717/primary-central-nervous-system-lymphoma-pcnsl-analysis-of-treatment-by-gamma-knife-radiosurgery-and-chemotherapy-in-a-prospective-observational-study
#12
Andres M Alvarez-Pinzon, Aizik L Wolf, Heather Swedberg, Sammie R Coy, Jose E Valerio
BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare cancer accounting for less than 3% of primary brain and central nervous system (CNS) tumors. Tissues involved include the brain parenchyma, leptomeninges, eyes, and spinal cord. High-dose methotrexate (MTX) is the gold standard for newly diagnosed PCNSL. However, Gamma Knife radiosurgery (GKRS) may be efficacious as a co-adjuvant treatment. The purpose of this prospective observational cohort study is to determine the effectiveness of MTX in combination with GKRS in the treatment of PCNSL...
July 18, 2016: Curēus
https://www.readbyqxmd.com/read/27530779/treatment-of-secondary-central-nervous-system-lymphoma-with-intrathecal-rituximab-high-dose-methotrexate-and-r-dhap-followed-by-autologous-stem-cell-transplantation-results-of-the-hovon-80-phase-2-study
#13
Jeanette K Doorduijn, Gustaaf W van Imhoff, Bronno van der Holt, Harry C Schouten, Martijn R Schaafsma, Marius A MacKenzie, Joke W Baars, Marie José Kersten, Pieternella J Lugtenburg, Martin J van den Bent, Roelien H Enting, Fokje M Spoelstra, Philip Poortmans, Jacoline E C Bromberg
The prognosis of central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma is poor with 1-year survival historically at 0% to 20%. Aiming to improve these results, we performed a multicenter phase 2 study in patients with a CNS relapse, with or without concurrent systemic relapse. Treatment consisted of 2 cycles of R-DHAP alternating with high-dose methotrexate (MTX) and was combined with intrathecal rituximab. Responding patients received a third R-DHAP-MTX cycle followed by busulfan and cyclophosphamide myeloablative therapy and autologous stem cell transplantation...
August 17, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27347188/long-term-remission-of-subcutaneous-panniculitis-like-t-cell-lymphoma-with-central-nervous-system-involvement-a-case-report
#14
Yajuan Qiu, Dandan Zhang, Mingzhi Zhang
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an indolent cutaneous T-cell lymphoma with a favourable prognosis. The reported incidence of central nervous system (CNS) involvement in SPTCL is extremely low. SPTCL with CNS involvement is a fatal disease with no optimal treatment. The present study presents the case of a 27-year-old man who initially presented with erythematous nodules on the left buttock and left inguinal lymph node enlargement. A skin biopsy resulted in a diagnosis of SPTCL. Subsequent to diagnosis, the patient developed CNS involvement and underwent treatment of fotemustine, teniposide and dexamethasone, and complete remission was achieved for 78 months...
July 2016: Oncology Letters
https://www.readbyqxmd.com/read/27339800/results-of-treatment-of-lymphoblastic-lymphoma-at-the-children-cancer-hospital-egypt-a-single-center-experience
#15
Hany Abdel Rahman Sayed, Mohamed Sedky, Asmaa Hamoda, Naglaa El Kinaaie, Madeha El Wakeel, Dina Hesham
Introduction Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are neoplasms of immature B or T-cell precursors. They are considered as a unique biological entity in the 2008 World Health Organization Classification of Hematologic Neoplasm. Both entities are arbitrarily separated by a cut-off point of 20-25% of blast cells in the bone marrow. Treatment of LBL has evolved over time from conventional high-grade NHL schedules to ALL-derived protocols. The aim of this work is to report the clinical characteristics, overall survival (OS), event free survival (EFS), and common chemotherapy toxicities of lymphoblastic lymphoma (LBL) patients during a 5...
September 2016: Journal of the Egyptian National Cancer Institute
https://www.readbyqxmd.com/read/27294357/osteopontin-in-cerebrospinal-fluid-as-diagnostic-biomarker-for-central-nervous-system-lymphoma
#16
Felicitas Strehlow, Sandra Bauer, Peter Martus, Michael Weller, Patrick Roth, Uwe Schlegel, Sabine Seidel, Carmen Scheibenbogen, Agnieszka Korfel, Stephan Kreher
Central nervous system lymphoma (CNSL) is diagnostically challenging. The identification of reliable and easy to measure biomarkers is desirable to facilitate diagnosis. Here, we evaluated the value of cerebrospinal fluid (CSF) osteopontin (OPN) as a diagnostic biomarker for CNSL. OPN concentrations in CSF from 37 patients with CNSL (29 with primary CNSL and 8 with secondary CNS involvement of systemic lymphoma) and 36 controls [6 patients with inflammatory CNS disease other than multiple sclerosis (MS), 8 with MS, 9 with glioblastoma (GBM) and 13 healthy controls] were determined using an enzyme-linked immunosorbent assay...
August 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27146613/pattern-of-malignancies-in-children-15-years-of-age-reported-in-hadhramout-cancer-registry-yemen-between-2002-and-2014
#17
Mazin A Jawass, Jalil I Al-Ezzi, Hanan S Bin Gouth, Saleh A Bahwal, Fawzia F Bamatraf, Abubakir A Ba'amer
OBJECTIVES: To describe the patterns of childhood cancers in Hadhramout Sector, Yemen between January 2002 and December 2014.  METHODS: This descriptive retrospective study was based on secondary data from Hadhramout Cancer Registry, Hadhramout, Yemen. All Yemeni children under age of 15 years, who were diagnosed with  cancer were included. The International Childhood Cancer Classification system was used to categorize cancer types.  RESULTS: A total of 406 childhood cancers of both gender less than 15 years of age were reported...
May 2016: Saudi Medical Journal
https://www.readbyqxmd.com/read/27069454/cerebral-toxoplasmosis-in-a-diffuse-large-b-cell-lymphoma-patient
#18
Lina Savsek, Tanja Ros Opaskar
BACKGROUND: Toxoplasmosis is an opportunistic protozoal infection that has, until now, probably been an underestimated cause of encephalitis in patients with hematological malignancies, independent of stem cell or bone marrow transplant. T and B cell depleting regimens are probably an important risk factor for reactivation of a latent toxoplasma infection in these patients. CASE REPORT: We describe a 62-year-old HIV-negative right-handed Caucasian female with systemic diffuse large B cell lymphoma who presented with sudden onset of high fever, headache, altered mental status, ataxia and findings of pancytopenia, a few days after receiving her final, 8(th) cycle of rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone (R-CHOP) chemotherapy regimen...
March 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27066337/unusual-relapse-of-primary-central-nervous-system-lymphoma
#19
Marielle Igala
Primary central nervous system lymphoma (PCNSL) is a rare disease which accounts for 1-2 % of non-Hodgkin lymphoma and 3-5 % of primary brain tumor lesions. PCNSL of an immunocompetent patient is an uncommon disease, it is estimated at 4 % of new diagnoses of CNS tumors. The prognosis of PCNSL is poor compared to other extranodal lymphomas, with a 5-year survival estimated between 20 and 40 %. PCNSL relapse occurs either in the original site but still confined to the CNS or exceptionally outside it. Brain magnetic resonance imaging, although not allowing a clear distinction between primary lesions and secondary brain lymphoma is of paramount importance not only for diagnosis but also for monitoring the patient...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27038652/lymphomatous-involvement-of-the-central-nervous-system
#20
REVIEW
G Bathla, A Hegde
Lymphoma may arise within the central nervous system (CNS), known as primary CNS lymphoma (PCNSL) or may involve the CNS secondary to systemic disease. Clinical features are non-specific. A provisional diagnosis of PCNSL can be made on imaging, potentially changing the management algorithm from neurosurgical resection to biopsy. PCNSL in immunocompetent patients generally presents late, is solid, is bright on diffusion weighted imaging and shows uniform enhancement. Contiguity with a cerebrospinal fluid (CSF) surface and perivascular enhancement are useful clues...
June 2016: Clinical Radiology
keyword
keyword
101599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"